Considering Survodutide

[brentm]

Not much activity here.... There's a vendor with a good price on Survodutide and I'm strongly considering picking up a couple kits to research.

Anyone have experiences good or bad with Survo? Care to share?

 

[clayd]

seems pretty quiet around here. if you do decide to try it out, would be great for you to post your experience here.
i'm not much familiar with it, i just did a quick google for clinical trials and it seems like weight loss results are about on par with semaglutide but not as good as tirzepatide. any specific reason you want to try it?

 

[clayd]

i saw that one trial, the highest dose was 4.8mg. promo price is 100mg for $170 so that's about 20 doses for $170, seems about the same per dose as tirz. (not saying that's good or bad, just working out the math here out loud)

 

[brentm]

seems pretty quiet around here. if you do decide to try it out, would be great for you to post your experience here.
i'm not much familiar with it, i just did a quick google for clinical trials and it seems like weight loss results are about on par with semaglutide but not as good as tirzepatide. any specific reason you want to try it?

I'm on Tirz now...

It's really between Retatrutide and Survodutide... Reta can cause an increase in resting heart rate, where Survo is reported not to have that side effect. That's the main reason I'm curious about Survo.

Why not blaze some new territory? But then Reta 100mg is 125 on promo...

 

[clayd]

yeah go for it, i realized after that my reply may have come across as argumentative, i didn't mean for it to. i'm curious about it too, and also curious how people make the decisions on which products to use. basically i originally chose tirz because it showed greater weight loss percentages than semaglutide and i needed to lose over 20%. but other people decide for different reasons (like the heart rate thing, some people decide on price, availability of compound, etc). i think it's interesting that it seems like people do develop a bit of loyalty to their first glp1 if it works for them.

but i haven't seen much talk about survo so was just wondering how it caught your attention.

if you go for it, good luck.

 

[brentm]

yeah go for it, i realized after that my reply may have come across as argumentative, i didn't mean for it to. i'm curious about it too, and also curious how people make the decisions on which products to use. basically i originally chose tirz because it showed greater weight loss percentages than semaglutide and i needed to lose over 20%. but other people decide for different reasons (like the heart rate thing, some people decide on price, availability of compound, etc). i think it's interesting that it seems like people do develop a bit of loyalty to their first glp1 if it works for them.

but i haven't seen much talk about survo so was just wondering how it caught your attention.

if you go for it, good luck.

Nah, I didn't take it as argumentative at all.

I started on Semaglutide because it was the lowest cost compound option. And I think my provider steered me that direction thinking we'd always have Tirz in our back pocket should Sema not work.

 

[chmuse]

I'm super interested in survo, but I have a freezer full of Sema and have some tirz arriving tomorrow.... I might just take the leap. I am just hesitant because I haven't seen anyone else on it. Keep meaning to join other forums to see if anyone has actually tried it.

 

[Lullabytreehugger]

This may help many of you guys out, have a look at the Ki values.

 

[chmuse]

This may help many of you guys out, have a look at the Ki values.

Google isn't helping me here and I'm feeling incredibly dumb for not quite understanding what these numbers mean.

 

[brentm]

Had to use chatgpt...

Google isn't helping me here and I'm feeling incredibly dumb for not quite understanding what these numbers mean.

The GLP-1 K value is a measure of the binding affinity of a ligand (such as a GLP-1 receptor agonist) to the GLP-1 receptor. GLP-1 (glucagon-like peptide-1) is a hormone that plays a role in glucose metabolism, and its receptor is a target for drugs used in the treatment of type 2 diabetes and obesity.

Key points about the GLP-1 K value:​

1. Definition of K value:
   
   • The "K" generally refers to a dissociation constant (KdK_dKd) or inhibition constant (KiK_iKi), depending on the context.
   • KdK_dKd: Reflects the concentration of ligand at which half of the available receptors are bound.
   • KiK_iKi: Indicates the potency of a compound in inhibiting receptor binding.
2. Units:
   
   • The KdK_dKd or KiK_iKi is typically expressed in molar concentrations (e.g., nM, μM).
   • Lower KdK_dKd or KiK_iKi values indicate higher affinity, meaning the ligand binds more tightly to the receptor.
3. Significance in GLP-1 receptor agonists:
   
   • A low K value suggests a strong and specific interaction between the drug and the GLP-1 receptor.
   • Drugs like semaglutide and liraglutide are engineered to have high affinity and prolonged activity at the GLP-1 receptor, often reflected in low KdK_dKd values.
4. Experimental determination:
   
   • The KKK value is determined through in vitro binding studies, using methods like radioligand binding assays or surface plasmon resonance.

The GCGR KiK_iKi value refers to the inhibition constant for the glucagon receptor (GCGR). It measures how effectively a compound, such as a drug or inhibitor, can block the interaction of glucagon (or another ligand) with the glucagon receptor.

Breaking Down the Term:​

1. GCGR (Glucagon Receptor):
   
   • GCGR is a G-protein-coupled receptor (GPCR) that binds glucagon, a hormone involved in glucose metabolism. Activation of GCGR stimulates glucose production in the liver, playing a key role in blood sugar regulation.
2. KiK_iKi (Inhibition Constant):
   
   • KiK_iKi quantifies the potency of an inhibitor in preventing a ligand (like glucagon) from binding to the receptor.
   • It is defined as the equilibrium constant for the dissociation of the inhibitor-receptor complex.
   • Lower KiK_iKi values indicate higher inhibitory potency because the compound binds more tightly to the receptor.
3. Units:
   
   • KiK_iKi is typically expressed in molar concentrations (e.g., nanomolar [nM] or micromolar [μM]).
4. How it’s Measured:
   
   • KiK_iKi is determined experimentally, often through competitive binding assays. These assays involve measuring how well an inhibitor competes with a radiolabeled or fluorescent ligand for binding to the receptor.
5. Significance:
   
   • KiK_iKi helps assess the efficacy of potential drugs targeting the glucagon receptor, particularly for conditions like type 2 diabetes.
   • Drugs with low KiK_iKi values for GCGR might act as antagonists to reduce excessive glucagon activity, which can help in managing hyperglycemia.

 

[chmuse]

Had to use chatgpt...



The GLP-1 K value is a measure of the binding affinity of a ligand (such as a GLP-1 receptor agonist) to the GLP-1 receptor. GLP-1 (glucagon-like peptide-1) is a hormone that plays a role in glucose metabolism, and its receptor is a target for drugs used in the treatment of type 2 diabetes and obesity.

Key points about the GLP-1 K value:​

1. Definition of K value:
   • The "K" generally refers to a dissociation constant (KdK_dKd) or inhibition constant (KiK_iKi), depending on the context.
   • KdK_dKd: Reflects the concentration of ligand at which half of the available receptors are bound.
   • KiK_iKi: Indicates the potency of a compound in inhibiting receptor binding.
2. Units:
   • The KdK_dKd or KiK_iKi is typically expressed in molar concentrations (e.g., nM, μM).
   • Lower KdK_dKd or KiK_iKi values indicate higher affinity, meaning the ligand binds more tightly to the receptor.
3. Significance in GLP-1 receptor agonists:
   • A low K value suggests a strong and specific interaction between the drug and the GLP-1 receptor.
   • Drugs like semaglutide and liraglutide are engineered to have high affinity and prolonged activity at the GLP-1 receptor, often reflected in low KdK_dKd values.
4. Experimental determination:
   • The KKK value is determined through in vitro binding studies, using methods like radioligand binding assays or surface plasmon resonance.

The GCGR KiK_iKi value refers to the inhibition constant for the glucagon receptor (GCGR). It measures how effectively a compound, such as a drug or inhibitor, can block the interaction of glucagon (or another ligand) with the glucagon receptor.

Breaking Down the Term:​

1. GCGR (Glucagon Receptor):
   • GCGR is a G-protein-coupled receptor (GPCR) that binds glucagon, a hormone involved in glucose metabolism. Activation of GCGR stimulates glucose production in the liver, playing a key role in blood sugar regulation.
2. KiK_iKi (Inhibition Constant):
   • KiK_iKi quantifies the potency of an inhibitor in preventing a ligand (like glucagon) from binding to the receptor.
   • It is defined as the equilibrium constant for the dissociation of the inhibitor-receptor complex.
   • Lower KiK_iKi values indicate higher inhibitory potency because the compound binds more tightly to the receptor.
3. Units:
   • KiK_iKi is typically expressed in molar concentrations (e.g., nanomolar [nM] or micromolar [μM]).
4. How it’s Measured:
   • KiK_iKi is determined experimentally, often through competitive binding assays. These assays involve measuring how well an inhibitor competes with a radiolabeled or fluorescent ligand for binding to the receptor.
5. Significance:
   • KiK_iKi helps assess the efficacy of potential drugs targeting the glucagon receptor, particularly for conditions like type 2 diabetes.
   • Drugs with low KiK_iKi values for GCGR might act as antagonists to reduce excessive glucagon activity, which can help in managing hyperglycemia.

Thank you, I appreciate this breakdown!